Zevra Therapeutics SG&A Expense (TTM) Analysis

Zevra Therapeutics Inc (ZVRA)

6.92 -0.39 (-5.34%) USD | NASDAQ | Sep 27, 16:00

6.92 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
June 30, 2024	43.01M
March 31, 2024	37.02M
December 31, 2023	34.31M
September 30, 2023	24.43M
June 30, 2023	22.58M
March 31, 2023	19.53M
December 31, 2022	15.04M
September 30, 2022	12.82M
June 30, 2022	10.80M
March 31, 2022	9.543M
December 31, 2021	8.701M
September 30, 2021	8.673M
June 30, 2021	8.154M
March 31, 2021	7.568M
December 31, 2020	7.921M
September 30, 2020	6.769M
June 30, 2020	8.953M
March 31, 2020	10.22M
December 31, 2019	10.82M
September 30, 2019	12.40M

Date	Value
June 30, 2019	11.78M
March 31, 2019	12.21M
December 31, 2018	12.51M
September 30, 2018	12.16M
June 30, 2018	12.48M
March 31, 2018	12.64M
December 31, 2017	12.77M
September 30, 2017	13.03M
June 30, 2017	12.82M
March 31, 2017	13.53M
December 31, 2016	14.00M
September 30, 2016	13.69M
June 30, 2016	12.74M
March 31, 2016	11.64M
December 31, 2015	8.883M
September 30, 2015	7.894M
June 30, 2015	6.828M
March 31, 2015	4.97M
December 31, 2014	4.527M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

6.769M

Minimum

Sep 2020

43.01M

Maximum

Jun 2024

15.96M

Average

10.81M

Median

SG&A Expense (TTM) Benchmarks